

aXichem Receives First Order from Uriach, for Aquilea's New Melatonin Formula Containing aXivite

aXichem AB (publ), a pioneer in the development and marketing of natural analogue industrial chemicals, is proud to announce a significant milestone in its partnership with [Uriach](#), one of Europe's oldest and most steadily growing pharmaceutical companies. Following the exclusive agreement signed in June of this year, Uriach has placed its first order related to the production of a new melatonin formula for its well-known brand Aquilea® featuring aXivite® as a new key ingredient. This marks the commencement of the product rollout, scheduled for April 2024. The total value of this first order is 21,500 Euro.

“The exclusive partnership with Uriach and the integration of aXivite into Aquilea's new formula highlight the potential and market demand for aXivite and its exceptional properties. Uriach's commitment to innovation and growth aligns well with our mission to provide science-based, natural health ingredients,” comments Torsten Helsing, CEO of aXichem.

In June 2023, aXichem and Uriach entered into a Supply and Research Agreement under which Uriach is granted exclusivity for a melatonin formulation with aXivite in the territories of Spain, Portugal, Germany, Austria, and Romania. To achieve this exclusivity Uriach, with a solid position in the Consumer Healthcare sector, is committed to a yearly minimum purchase of aXivite worth of 400,000 Euro. In April 2024 Spain will be the first market to experience Aquilea's new formula containing aXivite. The roll-out will then continue market by market, further expanding the reach and impact of aXivite in the dietary supplement market.

About phenylcapsaicin and aXivite

aXichem's proprietary molecule, phenylcapsaicin, combines the naturally occurring phenyl group with capsaicin, connected by a triple bond. The result is an innovative natural analog capsaicin with high purity, which in several studies has been shown to have the same health-promoting properties, as well as some unique benefits, as natural capsaicin. Phenylcapsaicin is approved under Novel Food in the EU and GRAS Food in the USA and is marketed for dietary supplements and functional foods under the brand name aXivite.

The information was submitted, through the care of the contact person below, for publication on 13 November 2023, at 14:30 CET.

Company contact:

Torsten Helsing, CEO, aXichem AB

Phone: +46 706 863 355 Email: torsten.helsing@axichem.com

About aXichem

aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.

More information is available at www.axichem.com.